Profile | GDS2987 / GI_31563385-A |
Title | Comparison of Rho kinase inhibitor and atorvastatin effects on primary cell lines |
Organism | Homo sapiens |
Sample | Title | Value | Rank |
---|---|---|---|
GSM214810 | HMVEC_vehicle_rep1 | 5.7 | 21 |
GSM215244 | HMVEC_vehicle_rep2 | 14 | 34 |
GSM215253 | HMVEC_vehicle_rep3 | 17.6 | 49 |
GSM215254 | HMVEC_atorvastatin_rep1 | 27.2 | 56 |
GSM215282 | HMVEC_atorvastatin_rep3 | 18.1 | 39 |
GSM215344 | HMVEC_atorvastatin_rep2 | ||
GSM215283 | HMVEC_atorvastatin_mevalonate_rep1 | 15 | 29 |
GSM215284 | HMVEC_atorvastatin_mevalonate_rep2 | 12.4 | 25 |
GSM215293 | HMVEC_atorvastatin_mevalonate_rep3 | 33 | 48 |
GSM215294 | HMVEC_SLx2119_rep1 | 23.5 | 60 |
GSM215295 | HMVEC_SLx2119_rep2 | 10.6 | 22 |
GSM215296 | HMVEC_SLx2119_rep3 | 26.8 | 42 |
GSM215297 | PASMC_vehicle_rep1 | ||
GSM215298 | PASMC_vehicle_rep2 | 79.9 | 70 |
GSM215310 | PASMC_vehicle_rep3 | 24.5 | 37 |
GSM215311 | PASMC_atorvastatin_rep1 | 18.6 | 32 |
GSM215312 | PASMC_atorvastatin_rep2 | 6.6 | 11 |
GSM215313 | PASMC_atorvastatin_rep3 | 21.6 | 31 |
GSM215324 | PASMC_atorvastatin_mevalonate_rep1 | 25.4 | 40 |
GSM215325 | PASMC_atorvastatin_mevalonate_rep2 | ||
GSM215326 | PASMC_atorvastatin_mevalonate_rep3 | 14.6 | 25 |
GSM215327 | PASMC_SLx2119_rep1 | 12.4 | 22 |
GSM215328 | PASMC_SLx2119_rep2 | 20.7 | 36 |
GSM215329 | PASMC_SLx2119_rep3 | 0.1 | 0 |
GSM215330 | Fibroblasts_vehicle_rep1 | 19.5 | 41 |
GSM215331 | Fibroblasts_vehicle_rep2 | 5.9 | 17 |
GSM215332 | Fibroblasts_vehicle_rep3 | 28.8 | 61 |
GSM215333 | Fibroblasts_atorvastatin_rep1 | 26.8 | 56 |
GSM215334 | Fibroblasts_atorvastatin_rep2 | 18.1 | 45 |
GSM215335 | Fibroblasts_atorvastatin_rep3 | 2 | 5 |
GSM215336 | Fibroblasts_atorvastatin_mevalonate_rep1 | ||
GSM215337 | Fibroblasts_atorvastatin_mevalonate_rep2 | 4 | 13 |
GSM215338 | Fibroblasts_atorvastatin_mevalonate_rep3 | 24.9 | 55 |
GSM215339 | Fibroblasts_SLx2119_rep1 | 27.2 | 58 |
GSM215340 | Fibroblasts_SLx2119_rep2 | 6.9 | 20 |
GSM215341 | Fibroblasts_SLx2119_rep3 | 10.1 | 26 |